Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe Wegovy 1mg pen is the third step in the semaglutide titration schedule, following 0.25mg and 0.5mg. Each 1mg dose is delivered once weekly by subcutaneous injection, using a pre-filled pen exactly as the Patient Information Leaflet describes. At this stage the licensed titration schedule, detailed by the NHS on their semaglutide medicine page, has been gradually raising your dose to help manage tolerability before you progress further. These are prescription-only medicines, so the technique, timing and any changes to your schedule are decisions made with your prescriber, not adjusted independently. If you have just started at this dose and feel uncertain about the injection process, that is entirely normal — most people do at this point.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy's titration pathway is built around tolerability, not speed. The STEP 1 trial, published in the New England Journal of Medicine, used a slow escalation precisely because gastrointestinal side effects are most pronounced when semaglutide is introduced or when the dose rises. By the time you reach 1mg, your system has already been through two adjustments. That context matters for how you interpret what you feel at this stage.
The 1mg pen is an intermediate dose, not the maintenance target. The licensed schedule continues from 1mg to 1.7mg and then to the 2.4mg maintenance dose, each step guided by your prescriber. Some people spend longer at a particular level if their body needs it. If you are wondering what the broader dose picture looks like across the schedule, the full Wegovy dose guide covers each stage in one place.
A prescriber decides when, and whether, to move you up. The pen itself does not signal that, your clinical review does.
The Wegovy 1mg pen uses the same injection mechanism as the other doses in the schedule. Hold the pen firmly, remove the cap, check the liquid is clear and colourless, and select your injection site. The three licensed sites are the abdomen (at least 5cm from the navel), the outer thigh, and the upper arm. Rotate the site each week, using the same spot repeatedly can cause changes to the tissue under the skin over time.
Pinch the skin gently if needed, hold the pen at 90 degrees, press the button, and hold it there until the injection is complete and the indicator window confirms it. Do not rub the injection site afterwards. The needle is fine-gauge; the physical sensation is brief for most people.
The 0.25mg starting dose guidance walks through the injection technique in the same level of detail, and if you are on the 5mg semaglutide pen, that format has its own step-by-step instructions worth reviewing before your first use. If you are moving up from the previous stage, the guidance on how to use the 0.5mg Wegovy pen covers the same handling steps and is useful to revisit as a reference point. The four-dose pen format used at some dose stages has slightly different handling, check which pen format your prescription covers. When in doubt, the Patient Information Leaflet inside your pen's box is the authoritative reference for the exact steps.
Nausea, loose stools, indigestion, fatigue, and headache are all commonly reported as semaglutide doses increase, according to NHS semaglutide guidance. At 1mg, these are often more noticeable than at 0.5mg. For many people they settle within one to two weeks as the body adjusts, but they do not disappear uniformly, and that can be discouraging.
Eating smaller portions, avoiding very fatty or heavily spiced food around injection day, and staying well-hydrated all tend to help. None of that replaces clinical advice, but it is what prescribers commonly suggest in practice.
There are symptoms that need prompt medical attention: severe, persistent abdominal pain that spreads to the back (which may signal pancreatitis, flagged in MHRA safety communications), signs of a serious allergic reaction, or significant dehydration from prolonged vomiting or diarrhoea. If something feels wrong, contact a healthcare professional rather than waiting for your next review. Suspected side effects can also be reported via the MHRA Yellow Card scheme, patients can use this directly, not just clinicians.
Because Wegovy is a prescription-only medicine, the 1mg pen requires a valid prescription from a registered prescriber, assessed for your circumstances. If you are exploring what a private prescription route looks like (including what the total cost covers) the Wegovy private prescription page sets out the process clearly.
At nume, a GPhC-registered Independent Prescriber reviews every consultation and every repeat. The same clinician-led process applies at this dose as at any other. If you have questions between reviews, our aftercare team is available seven days a week. The 1mg stage is often the point where people start to feel the medicine working, appetite shifts become more consistent, and the weekly routine starts to feel normal. Speak to our prescribers to understand whether this dose is right for your next step, or to start your assessment, via our free consultation page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.